Please assess the completion status of the following clinical trial:

Trial Title: Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Greater than or equal to 18 years of age~2. Hospitalized for acute decompensated heart failure (ADHF) secondary to fluid overload as defined by the presence of at least~   * 1 symptom (e.g. dyspnea, orthopnea, paroxysmal nocturnal dyspnea) AND~  * 1 sign (e.g. rales on auscultation, \> 2+ peripheral or presacral\> edema, hepatomegaly, ascites, jugular vein distension \> 7 cm, pulmonary vascular congestion on chest radiography)~3. Inadequate response to IV diuretics and requiring additional diuresis as determined by primary medical team~4. Received less than six doses of IV furosemide OR enrolled within 72 hours of hospital admission~5. Anticipated need for intravenous diuretic therapy for at least 48 hours~6. Able to provide informed consent~Exclusion Criteria:~1. Receiving a continuous infusion loop diuretic during current hospital visit~2. Substantial diuretic response to pre-randomization diuretic dosing such that higher doses of diuretic would be contraindicated (based on judgement of patient's primary team)~3. Planned or ongoing intravenous vasoactive therapy (e.g. inotrope, vasodilator) or mechanical support (e.g. intra-aortic balloon pump, ventricular assist device) for ADHF during this hospitalization~4. Planned elective admission for elective placement/revision of a cardiovascular device (e.g. defibrillator, biventricular pacemaker) during this hospitalization or such within the preceding 7 days~5. Systolic blood pressure \< 90 mmHg~6. Serum creatinine \> 3 mg/dL at baseline or renal replacement therapy including ultrafiltration~7. Serum potassium \< 3.5 mEq/L (3.0 - 3.4 mEq/L allowed if supplemental potassium is being administered)~8. Serum magnesium \< 1.6 mg/dL (1.4 - 1.5 mg/dL allowed if supplemental magnesium is being administered)~9. Acute coronary syndrome or hemodynamically significant arrhythmias causing worsening HF~10. Severe, uncorrected primary cardiac valvular disease, acute myocarditis, constrictive pericarditis, hypertrophic obstructive cardiomyopathy, restrictive or constrictive cardiomyopathy, complex congenital heart disease~11. Primary pulmonary hypertension with right sided heart failure~12. Use of iodinated radiocontrast material in prior 72 hours or planned within the next 48 hours~13. Enrollment or planned enrollment in another randomized clinical trial during hospitalization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Addition of PO Thiazide Diuretic (Type: ACTIVE_COMPARATOR): Addition of oral metolazone 5 mg daily to current intravenous bolus furosemide. All subjects will continue their current dose of intravenous bolus furosemide.
- IV furosemide dose escalation (Type: ACTIVE_COMPARATOR): Current IV furosemide dose will be escalated to 2-2.5 x current dose, given as either IV bolus or continuous infusion over 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).